These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 28083711

  • 21. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
    Sazawal S, Chikkara S, Singh K, Chaubey R, Chandra D, Mishra P, Mahapatra M, Seth T, Saxena R.
    Ann Diagn Pathol; 2017 Apr; 27():24-27. PubMed ID: 28325357
    [Abstract] [Full Text] [Related]

  • 22. Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
    Yin XF, Ma QL, Mu QT, Shao L, Wang SS, Meng HT, Xu WL, Wang YG, Chen ZM, Chen FF, Jin J.
    Leuk Res; 2014 Oct; 38(10):1191-8. PubMed ID: 25115808
    [Abstract] [Full Text] [Related]

  • 23. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F.
    Int J Mol Sci; 2019 May 06; 20(9):. PubMed ID: 31064152
    [Abstract] [Full Text] [Related]

  • 24. Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.
    Kjaer L, Skov V, Andersen MT, Aggerholm A, Clair P, Gniot M, Soeby K, Udby L, Dorff MH, Hasselbalch H, Pallisgaard N.
    Eur J Haematol; 2019 Jul 06; 103(1):26-34. PubMed ID: 30985947
    [Abstract] [Full Text] [Related]

  • 25. BCR/ABL1 Transcripts in Healthy Individuals: A Comparative Analysis Between First-Degree Relatives of Patients with Chronic Myelogenous Leukemia and Subjects without Antecedents of the Disease.
    Meza-Espinoza JP, Vásquez-Jiménez EA, Barajas-Torres RL, Magaña-Torres MT, González-García JR.
    Ann Clin Lab Sci; 2019 Nov 06; 49(6):703-709. PubMed ID: 31882420
    [Abstract] [Full Text] [Related]

  • 26. Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia.
    Patel KD, De M, Jethva DD, Rathod BS, Patel PS.
    Arch Med Res; 2022 Jan 06; 53(1):51-58. PubMed ID: 34275666
    [Abstract] [Full Text] [Related]

  • 27. Assessment of response to imatinib therapy in patients with chronic myeloid leukemia with e13a2 and e14a2 transcripts of BCR/ABL1 gene.
    Dmytrenko IV, Fedorenko VG, Shlyakhtychenko TY, Sholoyko VV, Lyubarets TF, Malinkina TV, Dmytrenko OO, Balan VV, Kravchenko SM, Martina ZV, Tovstogan AO, Minchenko JM, Dyagil IS.
    Probl Radiac Med Radiobiol; 2015 Dec 06; 20():328-40. PubMed ID: 26695912
    [Abstract] [Full Text] [Related]

  • 28. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.
    Am J Hematol; 2015 Apr 06; 90(4):282-7. PubMed ID: 25530131
    [Abstract] [Full Text] [Related]

  • 29. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G.
    Clin Lymphoma Myeloma Leuk; 2016 Aug 06; 16 Suppl():S96-S100. PubMed ID: 27131622
    [Abstract] [Full Text] [Related]

  • 30. Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
    Dulucq S, Etienne G, Morisset S, Klein E, Chollet C, Robbesyn F, Turcq B, Tigaud I, Hayette S, Nicolini FE, Mahon FX.
    Ann Hematol; 2019 May 06; 98(5):1159-1168. PubMed ID: 30798348
    [Abstract] [Full Text] [Related]

  • 31. Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report.
    Manzella L, Tirrò E, Vitale SR, Puma A, Consoli ML, Tambè L, Pennisi MS, DI Gregorio S, Romano C, Tomarchio C, DI Raimondo F, Stagno F.
    In Vivo; 2020 May 06; 34(3):1481-1486. PubMed ID: 32354950
    [Abstract] [Full Text] [Related]

  • 32. Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.
    Inokuchi K, Nakayama K, Tauchi T, Takaku T, Yokose N, Yamaguchi H, Kumagai T, Komatsu N, Ohyashiki K.
    Leuk Res; 2018 Feb 06; 65():74-79. PubMed ID: 29310021
    [Abstract] [Full Text] [Related]

  • 33. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
    Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann VS, Castagnetti F, Hasford J, Hehlmann R, Simonsson B.
    Leukemia; 2016 Jan 06; 30(1):48-56. PubMed ID: 26416462
    [Abstract] [Full Text] [Related]

  • 34. Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.
    Martínez-Castillo M, Gómez-Romero L, Tovar H, Olarte-Carrillo I, García-Laguna A, Barranco-Lampón G, De la Cruz-Rosas A, Martínez-Tovar A, Hernández-Zavala A, Córdova EJ.
    Leuk Res; 2023 Aug 06; 131():107325. PubMed ID: 37302352
    [Abstract] [Full Text] [Related]

  • 35. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
    Marcé S, Xicoy B, García O, Cabezón M, Estrada N, Vélez P, Boqué C, Sagüés M, Angona A, Teruel-Montoya R, Ferrer-Marín F, Amat P, Hernández-Boluda JC, Ibarra MM, Anguita E, Cortés M, Fernández-Ruiz A, Fontanals S, Zamora L, On Behalf Of The Grupo Español de Leucemia Mieloide Crónica Gelmc.
    J Clin Med; 2021 Jul 16; 10(14):. PubMed ID: 34300312
    [Abstract] [Full Text] [Related]

  • 36. Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib.
    Genthon A, Nicolini FE, Huguet F, Colin-Gil C, Berger M, Saugues S, Janel A, Hayette S, Cohny-Makhoul P, Cadoux N, Cayuela JM, Campos L, Guyotat D, Flandrin-Gresta P.
    Oncotarget; 2020 Jun 30; 11(26):2560-2570. PubMed ID: 32655840
    [Abstract] [Full Text] [Related]

  • 37. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
    Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.
    Cancer Med; 2020 Dec 30; 9(23):8931-8939. PubMed ID: 33037866
    [Abstract] [Full Text] [Related]

  • 38. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
    Eskazan AE, Sadri S, Keskin D, Ayer M, Kantarcioglu B, Demirel N, Aydin D, Aydinli F, Yokus O, Ozunal IE, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T.
    Clin Lymphoma Myeloma Leuk; 2017 Dec 30; 17(12):804-811. PubMed ID: 28847475
    [Abstract] [Full Text] [Related]

  • 39. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
    Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller MC, Hehlmann R, Hofmann WK, Fabarius A, Seifarth W, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, German CML Study Group.
    PLoS One; 2015 Dec 30; 10(6):e0129648. PubMed ID: 26087013
    [Abstract] [Full Text] [Related]

  • 40. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H, Tabe Y, Ai T, Tsuchiya K, Yuri M, Misawa S, Horii T, Kawaguchi A, Ohsaka A, Kimura S.
    PLoS One; 2019 Dec 30; 14(3):e0207170. PubMed ID: 30835732
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.